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ABSTRACT  
Tobacco smoking increases the risk of at least 17 classes of cancer. We analyzed somatic mutations 
and DNA methylation in 5,243 cancers of types for which tobacco smoking confers an elevated risk. 
Smoking is associated with increased mutation burdens of multiple distinct mutational signatures, 
which contribute to different extents in different cancers. One of these signatures, mainly found in 
cancers derived from tissues directly exposed to tobacco smoke, is attributable to misreplication of 
DNA damage caused by tobacco carcinogens. Others likely reflect indirect activation of DNA editing 
by APOBEC cytidine deaminases and of an endogenous clock-like mutational process. Smoking is 
associated with limited differences in methylation. The results are consistent with the proposition 
that smoking increases cancer risk by increasing the somatic mutation load, although direct evidence 
for this mechanism is lacking in some smoking-related cancer types.  
 
ONE SENTENCE SUMMARY: Multiple distinct mutational processes associated with tobacco smoking 
in cancer reflect direct and indirect effects of tobacco smoke. 
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MAIN TEXT 
Tobacco smoking has been associated with at least 17 types of human cancer (Table 1) and claims 
the lives of more than six million people every year (1-4). Tobacco smoke is a complex mixture of 
chemicals among which at least 60 are carcinogens (5). Many of these are thought to cause cancer 
by inducing DNA damage which, if misreplicated, leads to an increased burden of somatic mutations 
and hence an elevated chance of acquiring “driver” mutations in cancer genes. Such damage is often 
in the form of covalent bonding of metabolically activated reactive species of the carcinogen to DNA 
bases, termed “DNA adducts” (6). Tissues directly exposed to tobacco smoke (e.g. lung) as well as 
some tissues not directly exposed (e.g. bladder) show elevated levels of DNA adducts in smokers and 
thus evidence of exposure to carcinogenic components of tobacco smoke (7, 8). 
Each biological process causing mutations in somatic cells leaves a mutational signature (9). Many 
cancers have a somatic mutation in the TP53 gene and catalogues of TP53 mutations compiled two 
decades ago enabled early exploration of these signatures (10) showing that lung cancers from 
smokers have more C>A transversions than lung cancers from non-smokers (11-14). To investigate 
mutational signatures using the thousands of mutation catalogues generated by systematic cancer 
genome sequencing, we recently described a framework in which each base substitution signature is 
characterized using a 96 mutation classification that includes the six substitution types together with 
the bases immediately 5’ and 3’ to the mutated base (15). The analysis extracts mutational 
signatures from mutation catalogues and estimates the number of mutations contributed by each 
signature to each cancer genome (15). Using this approach, more than 30 different base substitution 
signatures have been identified (16-18).  
Here, we studied 5,243 cancer genome sequences (4,633 exomes and 610 whole genomes) of cancer 
classes for which smoking increases risk to identify mutational signatures and methylation changes 
associated with tobacco smoking (Table S1). 2,490 samples were reported to be from tobacco 
smokers and 1,063 from never smokers (Table 1) enabling investigation of the mutational 
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consequences of smoking by comparing somatic mutations and methylation in smokers with non-
smokers for lung, larynx, pharynx, oral cavity, esophagus, bladder, liver, cervix, kidney and pancreas 
cancers (Fig. 1 and Table S2). 
We first compared total numbers of base substitutions, small insertions and deletions (indels) and 
genomic rearrangements. Total base substitutions were higher in smokers compared to non-
smokers for all cancer types together (q-value<0.05) and, for individual cancer types, in lung 
adenocarcinoma, larynx, liver and kidney cancers (Table S2). Total numbers of indels were higher in 
smokers compared to non-smokers in lung adenocarcinoma and liver cancer (Table S2). The whole 
genome sequenced cases allowed comparison of genome rearrangements between smokers and 
non-smokers in pancreatic and liver cancer, where no differences were found (Table S2). However, 
sub-chromosomal copy number changes entail genomic rearrangement and can serve as surrogates 
for rearrangements. Lung adenocarcinomas from smokers exhibited more copy number aberrations 
than from non-smokers (Table S2).  
We then extracted mutational signatures, estimated the contributions of each signature to each 
cancer and compared the numbers of mutations attributable to each signature in smokers and non-
smokers. Increases in smokers compared to non-smokers were seen for signatures 2, 4, 5, 13 and 16 
(the mutational signature nomenclature is that used in COSMIC and references (16-18)). There was 
sufficient statistical power to show that these increases were of clonal mutations (mutations present 
in all cells of each cancer) for signatures 4 and 5 (q-value<0.05) as expected if they are due to 
cigarette smoke exposure prior to neoplastic change (Supplementary Text). 
Signature 4 is characterized mainly by C>A mutations with smaller contributions from other base 
substitution classes (Fig. 2B and Fig. S1). It was found only in cancer types in which tobacco smoking 
increases risk and mainly in those derived from epithelia directly exposed to tobacco smoke (Fig. S2 
and S3). Signature 4 is very similar to the mutational signature induced in vitro by exposing cells to 
benzo[a]pyrene (cosine similarity=0.94; Figs. 2B and S3), a tobacco smoke carcinogen (19). The 
 5 
similarity extends to the presence of a transcriptional strand bias indicative of transcription-coupled 
nucleotide excision repair (NER) of bulky DNA adducts on guanine (Fig. S1), the proposed mechanism 
of DNA damage by benzo[a]pyrene. Thus, signature 4 is likely the direct mutational consequence of 
misreplication of DNA damage induced by tobacco carcinogens. 
Most lung and larynx cancers from smokers had many signature 4 mutations. There were more 
signature 4 mutations in cancers from smokers compared to non-smokers in all cancer types 
together (Table S2) and in lung squamous, lung adenocarcinoma and larynx cancers (Table S2) 
accounting, in large part, for differences in total numbers of base substitutions (Table 1). 13.8% of 
lung cancers in non-smokers showed many signature 4 mutations (Fig. 2A;>1 mutation per MB) 
which may be due to passive smoking, misreporting of smoking habits or annotation errors. 
Signature 4 mutations were also found in oral cavity, pharynx and esophagus cancers, albeit in much 
smaller numbers than in lung and larynx cancers perhaps due to less exposure to tobacco smoke or 
more efficient clearance. Differences in mutation burden attributed to signature 4 between smokers 
and non-smokers were not observed in these cancer types (Fig. 1). Signature 4 mutations were 
found at low levels in cancers of the liver, an organ not directly exposed to tobacco smoke, and were 
elevated in smokers compared to non-smokers (Fig. 1). 
Signature 4 was not extracted from bladder, cervix, kidney or pancreas cancers, despite the known 
risks conferred by smoking and the presence of many smokers in these series. It was also not 
extracted from cancers of the stomach, colorectum, ovary and acute myeloid leukemia for which the 
smoking status in the analyzed series was unknown but among which many are likely to have been 
smokers. The tissues from which all these cancer types are derived are not directly exposed to 
tobacco smoke. Simulations indicate that the lack of signature 4 is not due to statistical limitations 
(Supplementary Text and Fig. S4). The absence of signature 4 suggests that misreplication of direct 
DNA damage due to tobacco smoke constituents does not contribute substantially to mutation 
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burden in these cancers even though DNA adducts indicative of tobacco-induced DNA damage are 
present in the tissues from which they arise (7). 
Signatures 2 and 13 are characterized by C>T and C>G mutations respectively at TpC dinucleotides 
and have been attributed to overactive DNA editing by APOBEC deaminases (20). The cause of the 
over-activity in most cancers has not been established although APOBECs are implicated in the 
cellular response to entrance of foreign DNA, retrotransposon movement and local inflammation 
(21). Signatures 2 and 13 showed more mutations in smokers than non-smokers in lung 
adenocarcinoma (Table S2). Since they are found in many other cancer types, where they are 
apparently unrelated to tobacco smoking, it seems unlikely that the signature 2 and 13 mutations 
associated with smoking in lung adenocarcinoma are direct consequences of misreplication of DNA 
damage induced by tobacco smoke. More plausibly, the cellular machinery underlying signatures 2 
and 13 is activated by tobacco smoke, perhaps as a result of inflammation arising from deposition of 
particulate matter or by indirect consequences of DNA damage. 
Signature 5 is characterized by mutations distributed across all 96 subtypes of base substitution, 
with predominance of T>C and C>T mutations (Fig. 2B) and evidence of transcriptional strand bias 
for T>C mutations (18). Signature 5 is found in all cancer types, including those unrelated to tobacco 
smoking, and in most cancer samples. It is “clock-like” in that the number of mutations attributable 
to this signature correlates with age of diagnosis in many cancer types (17). Signature 5, together 
with signature 1, is thought to contribute to mutation accumulation in most normal somatic cells 
and in the germline (17, 22). The mechanisms underlying signature 5 are not well understood, 
although an enrichment of signature 5 mutations was found in bladder cancers harboring 
inactivating mutations in ERCC2 which encodes a component of NER (23). 
Signature 5 (or a similar signature that is difficult to differentiate from it because of their relatively 
flat profiles) was increased between 1.3-fold and 5.1-fold (q-value<0.05; Table S2) in smokers 
compared to non-smokers in all cancer types together and in lung squamous, lung adenocarcinoma, 
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larynx, pharynx, oral cavity, esophageal squamous, bladder, liver and kidney cancers. The association 
of smoking with signature 5 mutations across these nine cancer types therefore includes some for 
which the risks conferred by smoking are modest and for which normal progenitor cells are not 
directly exposed to cigarette smoke (Table 1). Given the clock-like nature of signature 5 (17), its 
presence in the human germline (22), its ubiquity in cancer types unrelated to tobacco smoking (18) 
and its widespread occurrence in non-smokers, it seems unlikely that signature 5 mutations 
associated with tobacco smoking are direct consequences of misreplication of DNA damaged by 
tobacco carcinogens. It is more plausible that smoking affects the machinery generating signature 5 
mutations (23). Presumably as a consequence of the effects of smoking, signature 5 mutations 
correlated with age of diagnosis in non-smokers (p-value:0.001) but not in smokers (p-value:0.59). 
Signature 16 is predominantly characterized by T>C mutations at ApT dinucleotides (Fig. 2B), exhibits 
a strong transcriptional strand bias consistent with almost all damage occurring on adenine (Fig. S5) 
and has only been found thus far in liver cancer. The underlying mutational process is currently 
unknown. Signature 16 exhibited a higher mutation burden in smokers compared to non-smokers in 
liver cancer (Table S2).  
For smokers with lung, larynx, pharynx, oral cavity, esophageal, bladder, liver, cervix, kidney and 
pancreas cancers quantitative data on cumulative exposure to tobacco smoke were available (Table 
S1). Total numbers of base substitution mutations positively correlated with pack years smoked for 
all cancer types together (q-value<0.05) and for lung adenocarcinoma (Table S3). For individual 
mutational signatures, correlations with pack years smoked were found in multiple cancer types for 
signatures 4 and 5 (Table S3). Signature 4 correlated with pack years in lung squamous, lung 
adenocarcinoma, larynx and liver cancers. Signature 5 correlated with pack years in all cancers 
together, in lung adenocarcinoma, pharynx, oral cavity and bladder cancers (Table S3). In lung 
adenocarcinoma, correlations with pack years smoked were also observed for signatures 2 and 13. 
The rates of these correlations allow estimation of the approximate numbers of mutations 
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accumulated in a normal cell of each tissue due to smoking a pack of cigarettes a day for a year: 
lung, 150 mutations; larynx, 97; pharynx, 39; oral cavity 23; bladder, 18; liver, 6 (Table S3).  
Consistent with our results, previous studies have reported the higher numbers in smokers 
compared to non-smokers of total base substitutions in lung adenocarcinoma (mainly due to C>A 
substitutions) (24, 25),  of signatures 4 and 5 in lung adenocarcinoma (18), of signature 4 in liver 
cancer (26) and of signature 5 in bladder cancer (23).  
Differential methylation of the DNA of normal cells of smokers compared to non-smokers has been 
reported (27). Using data from methylation arrays, each containing ~470,000 of the ~28 million CpG 
sites in the human genome, we evaluated whether differences in methylation are found in cancers. 
Overall levels of CpG methylation in DNA from cancers were similar in smokers and non-smokers for 
all cancer types (Fig. S6). Individual CpGs were differentially methylated (>5% difference) only in two 
cancer types: 369 CpGs were hypo- and 65 were hyper-methylated in lung adenocarcinoma, with 5 
hypo- and 3 hyper-methylated in oral cancer (Fig. 3 and S7). CpGs exhibiting differences in 
methylation clustered in certain genes but were neither associated with known cancer genes more 
than expected by chance nor with genes hypo-methylated in normal blood or buccal cells of tobacco 
smokers (Fig. S8; Tables S4 and S5) (27). Therefore, with the exception of lung cancer, CpG 
methylation showed limited differences between the cancers of smokers and non-smokers (Fig. 3). 
The genomes of smoking-associated cancers permit reassessment of our understanding of how 
tobacco smoke causes cancer. Consistent with the proposition that an increased mutation load 
caused by tobacco smoke contributes to increased cancer risk, the total mutation burden is elevated 
in smokers compared to non-smokers in lung adenocarcinoma, larynx, liver and kidney cancers. 
However, differences in total mutation burden were not observed in the other smoking-associated 
cancer types and in some there were no statistically significant smoking-associated differences in 
mutation load, signatures or DNA methylation. Caution should be exercised in the interpretation of 
the latter observations. In addition to limitations of statistical power, multiple rounds of clonal 
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expansion over many years are often required for development of a symptomatic cancer. It is thus 
conceivable that, in the normal tissues from which smoking associated cancer types originate, there 
are more somatic mutations in smokers than in non-smokers (or differences in methylation) but that 
these differences become obscured during the intervening clonal evolution. Moreover, some 
theoretical models predict that relatively small differences in mutation burden caused by smoking in 
pre-neoplastic cells could account for the observed increases in cancer risks (28) and others that 
differences in mutation burden between smokers and non-smokers need not be observed in the 
final cancers (Supplementary Text and Fig. S6). Thus, increased somatic mutation loads in 
precancerous tissues may still explain the smoking-induced risks of most cancers, although other 
mechanisms have been proposed (29, 30).  
The generation of the increased somatic mutation burden by tobacco smoking, however, appears to 
be mechanistically complex. Smoking correlates with increases in base substitutions of multiple 
mutational signatures, together with increases in indels and copy number changes. The extent to 
which these distinct mutational processes operate differs between tissue types, at least in part 
depending on the degree of direct exposure to tobacco smoke, and their mechanisms range from 
misreplication of DNA damage caused by tobacco smoke constituents to activation of more generally 
operative mutational processes. Although we cannot exclude roles for covariate behaviours of 
smokers or differences in the biology of cancers arising in smokers compared to non-smokers, 
smoking itself is most plausibly the cause of these differences. 
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FIGURE LEGENDS 
Fig. 1. Comparison between tobacco smokers and lifelong non-smokers. Bars are used to display 
average values for numbers of somatic substitutions per megabase, numbers of indels per 
megabase, numbers of dinucleotide mutations per megabase, numbers of breakpoints per 
megabase, fraction of the genome that shows copy number changes and numbers of mutations per 
megabase attributed to mutational signatures found in multiple cancer types associated with 
tobacco smoking. Light gray bars are non-smokers, while dark gray bars are smokers. Comparisons 
between smokers and non-smokers for all features, including mutational signatures specific for a 
cancer type and overall DNA methylation are provided in Table S2. Error bars correspond to 95% 
confidence intervals for each feature. Each q-value is based on a two-sample Kolmogorov-Smirnov 
test corrected for multiple hypothesis testing for all features in a cancer type. Cancer types are 
ordered based on their age adjusted odds ratios for smoking as provided in Table 1. Data for 
numbers of breakpoints per megabase and fraction of the genome that shows copy number changes 
were not available for liver cancer and small cell lung cancer. Adeno stands for Adenocarcinoma; 
Esophag. stands for Esophagus. Note that the presented data include only a few cases (<10) of 
nonsmokers for lung small cell, lung squamous and cancer of the larynx. 
 
Fig. 2. Mutational signatures associated with tobacco smoking. (A) Each panel contains 25 
randomly selected cancer genomes (represented by individual bars) from either smokers or non-
smokers in a given cancer type. The y-axes reflect numbers of somatic mutations per megabase. 
Each bar is colored proportionately to the numbers of mutations per megabase attributed to the 
mutational signatures found in that sample. Naming of mutational signatures is consistent with 
previous reports (16-18). (B) Each panel contains the pattern of a mutational signature associated 
with tobacco smoking. Signatures are depicted using a 96 substitution classification defined by the 
substitution type and sequence context immediately 5’ and 3’ to the mutated base. Different colors 
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are used to display different types of substitutions. The percentages of mutations attributed to 
specific substitution types are on the vertical axes, while the horizontal axes display different types 
of substitutions. Mutational signatures are depicted based on the trinucleotide frequency of the 
whole human genome. Signatures 2, 4, 5, 13 and 16 are extracted from cancers associated with 
tobacco smoking. The signature of benzo[a]pyrene is based on in vitro experimental data (19). 
Numerical values for these mutational signatures are provided in Table S6. 
 
Fig. 3. Differentially methylated individual CpGs in tobacco smokers across cancers associated with 
tobacco smoking. Each dot represents an individual CpG. The horizontal axes reflect differences in 
methylation between lifelong non-smokers and smokers, where positive values correspond to hyper-
methylation and negative values to hypo-methylation. The vertical axes depicted levels of statistical 
significance. Results satisfying a Bonferroni threshold of 10-7 (above the red line) are considered 
statistically significant. 
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TABLES 
Cancer Type Odds ratios 
Non-
smokers Smokers 
Total number of 
mutational 
signatures found 
in the cancer type 
Signature 4 
found in 
cancer 
type  
Mutational signatures 
with elevated mutation 
burden in smokers 
compared to non-
smokers (q-value<0.05) 
All Cancer Types  1,062 2,490 
26 Y 4, 5* 
Small Cell Lung Cancer 111.3 3 145 6 Y  
Lung Squamous 103.5 7 168 8 Y 4*, 5 
Lung Adenocarcinoma 21.9 120 558 7 Y 2*, 4*, 5*, 13* 
Larynx 13.2 6 117 5 Y 4*, 5 
Pharynx 6.6 27 49 5 Y 5* 
Oral Cavity 4.2 98 265 5 Y 5* 
Esophagus Squamous 3.9 99 193 9 Y 5 
Esophagus Adenocarcinoma 3.9 67 175 9 Y  
Bladder 3.8 111 288 5 N 5* 
Liver 2.9 157 235 19 Y 4*, 5, 16 
Stomach 2.1 472 13 N N/A 
Acute Myeloid Leukemia 2.0 202 2 N N/A 
Ovary 1.9 458 3 N N/A 
Cervix 1.8 94 74 8 N  
Kidney 1.7 154 103 6 N 5 
Pancreas 1.6 119 120 11 N  
Colorectal 1.3 559 4 N N/A 
 
Table 1. Mutational signatures and cancer types associated with tobacco smoking. Information 
about the age adjusted odds ratios for current male smokers to develop cancer is taken from refs. 
(2-4). Odds ratios for small cell lung cancer, lung squamous and lung adenocarcinoma are for an 
average daily dose of more than 30 cigarettes. Odds ratios for cervix and ovary are for current 
female smokers. Detailed information about all mutation types, all mutational signatures and DNA 
methylation is provided in Table S2. Nomenclature for signature IDs is consistent with the COSMIC 
website, http://cancer.sanger.ac.uk/cosmic/signatures. The patterns of all mutational signatures 
with elevated mutation burden in smokers are displayed in Fig. 2B. N/A denotes lack of smoking 
annotation for a given cancer type. * denotes that a signature correlates with pack years smoked in 
a cancer type. 
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